Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Merck's other long-term liabilities for the quarter that ended in Jun. 2026 was CHF6,053 Mil.
Merck's quarterly other long-term liabilities
declined
from Dec. 2025 (CHF6,127 Mil) to Mar. 2026 (CHF6,017 Mil) but then
increased
from Mar. 2026 (CHF6,017 Mil) to Jun. 2026 (CHF6,053 Mil).
Merck's annual other long-term liabilities
declined
from Dec. 2023 (CHF7,603 Mil) to Dec. 2024 (CHF5,764 Mil) but then
increased
from Dec. 2024 (CHF5,764 Mil) to Dec. 2025 (CHF6,127 Mil).
The historical data trend for Merck's Other Long-Term Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.
What does a Other Long-Term Liabilities of CHF6,053 Mil mean?
Merck (XSWX:MRK) has a Other Long-Term Liabilities of CHF6,053 Mil as of Jun. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Merck and its competitors.
Is Merck's Other Long-Term Liabilities too high?
Merck's current Other Long-Term Liabilities is CHF6,053 Mil. Overall, Merck has a GF Score™ of 71/100, reflecting its overall financial health beyond just this single metric.
How does Merck's Other Long-Term Liabilities compare to AMGN and ABBV?
Merck's Other Long-Term Liabilities of CHF6,053 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Drug Manufacturers company?
A good Other Long-Term Liabilities depends on the Drug Manufacturers industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Merck and its competitors. Merck's current Other Long-Term Liabilities is CHF6,053 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Merck stock overvalued right now?
Merck (XSWX:MRK) has a current Other Long-Term Liabilities of CHF6,053 Mil. The stock's GF Value™ is CHF95.97, compared to a current price of CHF122.12 — trading 27.2% above its estimated fair value. The current Other Long-Term Liabilities is CHF6,053 Mil. Merck's overall GF Score™ is 71/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Merck (XSWX:MRK), the current Other Long-Term Liabilities is CHF6,053 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Merck (XSWX:MRK) Overvalued in 2026?
Based on GuruFocus' analysis, Merck stock appears to be overvalued.
The current stock price of CHF122.12 is trading 27.2% above its estimated GF Value™ of CHF95.97.
Key valuation signals for XSWX:MRK:
Other Long-Term Liabilities: CHF6,053 Mil
GF Value™: CHF95.97 vs. price of CHF122.12 (27.2% above fair value)
No single metric tells the full story. See the XSWX:MRK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
71GF Score
Get the complete analysis for XSWX:MRK
Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:MRK has been successfully added to your 
